Korean cohort study for outcomes in chronic kidney disease
Official title: KoreaN Cohort Study for Outcome in Patients With Chronic Kidney Disease: A Longitudinal Cohort Study of the Chronic Kidney Disease (KNOW-CKD), Phase II Study
Run by Seoul National University Hospital · NCT03929900 · Data updated 2026-11-12
This study is trying to follow a group of people with chronic kidney disease in South Korea for up to 10 years to see how their condition changes and what factors affect their health.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 45 Years to 79 Years |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Seoul National University Hospital Academic / other |
| Locations | 1 site (Seoul, Jongno-gu) |
| Status | Recruiting |
| Started | May 15, 2019 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | June 4, 2019 |
| Trial ID | NCT03929900 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are individuals aged 45-79 years with an estimated glomerular filtration rate of 20-60 mL/min/1.73m² who are not dependent on dialysis.
✕Probably not a fit
Patients with autosomal dominant polycystic kidney disease, those who have previously received chronic dialysis, or individuals with severe heart failure may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The KNOW-CKD study aims to establish a cohort of chronic kidney disease (CKD) patients in South Korea for up to 10 years to investigate renal progression, mortality, complications, and risk factors. It involves a comprehensive evaluation of kidney function, biochemical parameters, and lifestyle factors, including nutrition and cognitive functions. Patients are enrolled based on specific causes of CKD and undergo regular follow-ups with laboratory tests and health assessments. The study utilizes web-based case-report forms for systematic data management.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the management and treatment of chronic kidney disease in the Korean population.
How similar studies have gone: Other studies focusing on CKD cohorts have shown success in understanding disease progression and improving patient outcomes, making this approach promising.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 45-79 years * Estimated glomerular filtration rate 20-60mL/min/1.73m2 based on CKD-EPI(Cr) equation * Non-dialysis dependent (NDD) Exclusion Criteria: * Autosomal dominant polycystic kidney disease * Unable or unwilling to give consent * Previously received chronic dialysis * Previous any organ transplant * Patients who diagnosed heart failure with NYHA class 3 or 4 * Known liver cirrhosis (Child-pugh class 2 or 3) * Pregnant women * Single kidney due to trauma or donation * Patients who received immunosuppressive agent within the past 1 year * Patients who diagnosed with glomerulonephritis through kidney biopsy
Where it's running
-
Seoul National University Hospital
Seoul, Jongno-gu, South Korea Recruiting
Study contacts
- Study coordinator: Kook-Hwan Oh, MD
- Email: khoh@snu.ac.kr
- Phone: 82 2 2072 0776
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Clinical decision support to help consider SGLT2 inhibitors after AKI in type 2 diabetes
This pilot test checks if a CDS message given to clinicians can help decide whether to consider SGLT2 inhibitors for adults with type 2 diabetes who recently had acute kidney injury.
-
Impact of TAVR on kidney function in people with aortic valve disease
This registry tests how trans-catheter aortic valve implantation affects kidney function and the risk of kidney injury in adults with aortic stenosis.
-
Calciphylaxis in people with chronic kidney disease: causes, risks, and early signs
This project will compare adults with chronic kidney disease who develop calciphylaxis to matched CKD patients who do not, collecting clinical data and biological samples to try to find risk factors and early signs.
-
Oral Semaglutide for CKD and MAFLD in adults with diabetes
This study tests whether adding oral semaglutide to standard care can slow kidney and liver disease progression in adults with CKD and MAFLD who have type 2 diabetes.
-
Eye-brain-kidney connections in chronic kidney disease
This study will see if changes in brain network connectivity and retinal blood vessels are linked to cognitive decline and kidney function in adults with chronic kidney disease.
-
Screening for chronic kidney disease
We will see how common chronic kidney disease is among adults followed at a tertiary care center and how many cases were previously undiagnosed.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.